U.S Physical Therapy Income from Discontinued Operations 2010-2024 | USPH

U.S Physical Therapy income from discontinued operations from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
U.S Physical Therapy Annual Income from Discontinued Operations
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $-5
2012 $-0
2011 $3
2010 $
2009 $
U.S Physical Therapy Quarterly Income from Discontinued Operations
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31 $-0
2013-09-30 $-4
2013-06-30 $-0
2013-03-31 $-0
2012-12-31 $-0
2012-09-30 $-0
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $1.463B $0.605B
U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $19.347B 11.70
Quest Diagnostics (DGX) United States $18.293B 18.54
DaVita (DVA) United States $13.459B 17.41
Encompass Health (EHC) United States $10.015B 23.61
Chemed (CHE) United States $8.477B 26.05
Elanco Animal Health (ELAN) United States $6.624B 15.77
RadNet (RDNT) United States $6.018B 133.28
Option Care Health (OPCH) United States $3.827B 18.14
Amedisys (AMED) United States $2.953B 21.02
LifeStance Health (LFST) United States $2.797B 0.00
Astrana Health (ASTH) United States $2.369B 32.39
Addus HomeCare (ADUS) United States $2.191B 25.71
Aveanna Healthcare Holdings (AVAH) United States $1.121B 0.00
Pennant (PNTG) United States $1.048B 42.36
Atai Life Sciences (ATAI) Germany $0.255B 0.00
Daxor (DXR) United States $0.043B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.015B 0.00
Psychemedics (PMD) United States $0.014B 0.00
Ontrak (OTRK) United States $0.008B 0.00
ATI Physical Therapy (ATIP) United States $0.007B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00